High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer - PubMed (original) (raw)
. 2013 Aug 15;191(4):2001-8.
doi: 10.4049/jimmunol.1300872. Epub 2013 Jul 3.
Affiliations
- PMID: 23825314
- DOI: 10.4049/jimmunol.1300872
High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer
Ludovic Martinet et al. J Immunol. 2013.
Abstract
Blood vessels and tumor angiogenesis are generally associated with tumor growth and poor clinical outcome of cancer patients. However, we recently discovered that some blood vessels present within the tumor microenvironment can be associated with favorable prognosis. These vessels, designated tumor high endothelial venules (HEVs), appear to facilitate tumor destruction by allowing high levels of lymphocyte infiltration into tumors. In this study, we investigated the mechanisms regulating HEV blood vessels in human breast cancer. We found that lymphotoxin β was overexpressed in tumors containing high densities of HEVs (HEV(high)) and correlated to DC-LAMP, a marker of mature DCs. DCs were the main producers of lymphotoxin β in freshly resected HEV(high) breast tumor samples, and the density of DC-LAMP(+) DCs clusters was strongly correlated with the density of tumor HEVs, T and B cell infiltration, and favorable clinical outcome in a retrospective cohort of 146 primary invasive breast cancer patients. Densities of tumor HEVs and DC-LAMP(+) DCs were strongly reduced during breast cancer progression from in situ carcinoma to invasive carcinoma, suggesting that loss of tumor HEVs is a critical step during breast cancer progression. Finally, an increase in the infiltration of regulatory T cells was observed in HEV(high) breast tumors, indicating that tumor HEVs can develop in the presence of regulatory T cells. Together, our results support a key role for DCs and DC-derived lymphotoxin in the formation of tumor HEVs. These findings are important because novel therapeutic strategies based on the modulation of tumor HEVs could have a major impact on clinical outcome of cancer patients.
Similar articles
- Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer.
Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, Rochaix P, Girard JP. Martinet L, et al. Cancer Res. 2011 Sep 1;71(17):5678-87. doi: 10.1158/0008-5472.CAN-11-0431. Epub 2011 Aug 16. Cancer Res. 2011. PMID: 21846823 - High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes.
Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, Garrido I, Girard JP. Martinet L, et al. Oncoimmunology. 2012 Sep 1;1(6):829-839. doi: 10.4161/onci.20492. Oncoimmunology. 2012. PMID: 23162750 Free PMC article. - Treg Depletion Licenses T Cell-Driven HEV Neogenesis and Promotes Tumor Destruction.
Colbeck EJ, Jones E, Hindley JP, Smart K, Schulz R, Browne M, Cutting S, Williams A, Parry L, Godkin A, Ware CF, Ager A, Gallimore A. Colbeck EJ, et al. Cancer Immunol Res. 2017 Nov;5(11):1005-1015. doi: 10.1158/2326-6066.CIR-17-0131. Epub 2017 Sep 25. Cancer Immunol Res. 2017. PMID: 28947544 Free PMC article. - Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
Chen XY, Yeong J, Thike AA, Bay BH, Tan PH. Chen XY, et al. Breast Cancer Res Treat. 2019 Aug;177(1):17-27. doi: 10.1007/s10549-019-05272-2. Epub 2019 May 27. Breast Cancer Res Treat. 2019. PMID: 31134489 Review. - Understanding high endothelial venules: Lessons for cancer immunology.
Ager A, May MJ. Ager A, et al. Oncoimmunology. 2015 May 7;4(6):e1008791. doi: 10.1080/2162402X.2015.1008791. eCollection 2015 Jun. Oncoimmunology. 2015. PMID: 26155419 Free PMC article. Review.
Cited by
- Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO.
Weinstein AM, Storkus WJ. Weinstein AM, et al. Front Immunol. 2016 Aug 9;7:301. doi: 10.3389/fimmu.2016.00301. eCollection 2016. Front Immunol. 2016. PMID: 27555845 Free PMC article. Review. - Mapping the complexity and diversity of tertiary lymphoid structures in primary and peritoneal metastatic gastric cancer.
Groen-van Schooten TS, Franco Fernandez R, van Grieken NCT, Bos EN, Seidel J, Saris J, Martínez-Ciarpaglini C, Fleitas TC, Thommen DS, de Gruijl TD, Grootjans J, Derks S. Groen-van Schooten TS, et al. J Immunother Cancer. 2024 Jul 1;12(7):e009243. doi: 10.1136/jitc-2024-009243. J Immunother Cancer. 2024. PMID: 38955417 Free PMC article. - Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Zhang Y, Wang F, Sun HR, Huang YK, Gao JP, Huang H. Zhang Y, et al. J Cancer Res Clin Oncol. 2021 Aug;147(8):2209-2222. doi: 10.1007/s00432-021-03633-3. Epub 2021 Apr 23. J Cancer Res Clin Oncol. 2021. PMID: 33891173 - Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity.
Chen L, Fabian KL, Taylor JL, Storkus WJ. Chen L, et al. Front Immunol. 2013 Nov 29;4:388. doi: 10.3389/fimmu.2013.00388. Front Immunol. 2013. PMID: 24348473 Free PMC article. Review. - Tertiary lymphoid structure and B-cell-related pathways: A potential target in tumor immunotherapy.
Qin M, Jin Y, Pan LY. Qin M, et al. Oncol Lett. 2021 Dec;22(6):836. doi: 10.3892/ol.2021.13097. Epub 2021 Oct 18. Oncol Lett. 2021. PMID: 34712360 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical